IP Library › Granted Patent US 12,735,444
Granted Patent B2
US 12,735,444 · App. 17/023,343 · Granted Sep 15, 2026

Chemically cleavable group

Inventors: Marc Stefan Robillard (Eindhoven, NL); Ronny Mathieu Versteegen (Eindhoven, NL); Wolter Ten Hoeve (Eindhoven, NL); Raffaella Rossin (Eindhoven, NL)
Assignee: Tagworks Pharmaceuticals B.V.
C07H15/252A61K47/555A61K47/60A61K47/6897B82Y5/00C07C29/10C07C37/50C07C45/61C07C205/20C07C205/57C07C209/62G01N33/54353G01N33/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,735,444
App. No.
17/023,343
Granted
Sep 15, 2026
Kind
B2
Abstract

Disclosed is the use of the reactive components of the inverse electron-demand Diels Alder reaction for chemical masking and unmasking in vitro. This can be applied in complex chemical reactions and, particularly in the synthesis of biomolecules, e.g. on solid supports. The reactice components are a dienophile, particularly a trans-cyclooctene, and a diene, particularly a tetrazine.

Claims (41)

1 . A dienophile of Formula (1a):

wherein A and P each independently are CH 2 , or CHX D , provided that at least one is CHX D ; X D is (O—C(O)) p -(L D ) n -(C A ), or O—C(S)-(L D ) n -(C A ); wherein n=0 or 1, wherein p=0 or 1; wherein when p=0, L D or C A is bound to the dienophile via O, S, aromatic N or aromatic NH; L D is a self-immolative linker consisting of one or more self-immolative units;

wherein each self-immolative unit is selected from the group consisting of

wherein the wiggly line indicates a bond to (O—C(O)) p or O—C(S) of X D , or to a preceding self-immolative unit; wherein the asterisk indicates a bond to C A or to a further self-immolative unit;

wherein L 2 is O, S, NH, or NR with R being alkyl or aryl; wherein each L 1 is independently H or methyl;

Y, Z, X, Q each independently are selected from the group consisting of CR a 2 , C═O, O, and NR b , with at most three of Y, Z, X, and Q being C═O, wherein two R moieties together may form a ring, and with the proviso that no adjacent pairs of atoms are present selected from the group consisting of O—O, and O—NR b ;

wherein each R a can independently be H, alkyl, aryl, OR′, SR′, S(═O) 2 R′″, S(═O) 2 NR′R″, SO 3 H, PO 3 H, NO 2 , CN, CF 3 , CF 2 —R′, NR′R″, C(═O)R′, C(═O)OH, C(═O)NR′R″, C(═S)NR′R″, NR′C(═O)—R′″, NR′C(═S)—R′″, NR′C(═O)O—R′″, NR′C(═S)O—R′″, NR′C(═O)S—R′″, NR′C(═S)S—R′″, OC(═O)NR′—R′″, SC(═O)NR′—R′″, OC(═S)NR′—R′″, SC(═S)NR′—R′″, NR′C(═O)NR″—R″, or NR′C(═S)NR″—R″, with each R′ and each R″ independently being H, aryl or alkyl and R′″ independently being aryl or alkyl;

wherein each R b is independently selected from the group consisting of H, alkyl, aryl, O-aryl, O-alkyl, OH, C(═O)NR′R″ with R′ and R″ each independently being H, aryl or alkyl, and R′CO-alkyl with R′ being H, alkyl, and aryl;

wherein one R a or R b is optionally bound to a construct C B ; and wherein the self-immolative linker L D , in addition to being bound to C A , is also optionally bound to a construct C B ; wherein T and G denote H;

wherein each C A and C B are individually selected from the group consisting of biomolecules, biomolecule-binding moieties, polymers, particles, gels, fluorophores, and radiolabels.

2 . The dienophile according to claim 1 , wherein p is 1.

3 . The dienophile according to claim 1 , wherein X D is (O—C(O)) p -(L D ) n -(C A ).

4 . The dienophile according to claim 1 , wherein the construct comprises a biomolecule-binding moiety selected from the group consisting of non-covalent binding moieties, and covalent binding moieties.

5 . The dienophile according to claim 4 , wherein the non-covalent binding moiety is biotin or an antibody.

6 . The dienophile according to claim 4 , wherein the covalent binding moiety is an N-hydroxysuccinimide ester, a maleimide, an azide, an alkyne, or a photoreactive group.

7 . The dienophile according to claim 1 , wherein the biomolecule is selected from the group consisting of carbohydrates, peptides, peptoids, lipids, proteins, oligonucleotides, DNA, RNA, PNA, LNA, aptamers, hormones, steroids, and toxins.

8 . The dienophile according to claim 7 , wherein the protein is an enzyme, cytokine, antibody, antibody fragment, antibody fusion, or an antibody fragment fusion.

9 . The dienophile according to claim 8 , wherein the antibody fragment is Fab2, Fab, scFV, a diabody, a triabody, or VHH.

10 . The dienophile according to claim 1 , wherein the particle is a bead, a gold particle, a silica-based particle, a glass particle, a polymer particle, an iron oxide particle, a microparticle, or a nanoparticle.

11 . The dienophile according to claim 10 , wherein the bead is a magnetic bead.

12 . The dienophile according to claim 10 , wherein the microparticle is a liposome or polymersome.

13 . The dienophile according to claim 10 , wherein the nanoparticle is a liposome or a polymersome.

14 . The dienophile according to claim 1 , wherein the polymer is a resin.

15 . The dienophile according to claim 1 , wherein one of the bonds PQ, QX, XZ, ZY, YA is part of a fused ring, such that two exocyclic bonds are fixed in the same plane, and provided that PQ and YA are not part of an aromatic 5- or 6-membered ring, or of a conjugated 7-membered ring; when not part of a fused ring P and A are independently CH 2 or CHX D , provided that at least one is CHX D ; when part of a fused ring P and A are independently CH or CX D , provided that at least one is CX D ; the remaining moieties Y, Z, X, and Q of the group (—Y—Z—X-Q-) being independently from each other CR a 2 , S, SO, SO 2 , O, or NR b , such that no adjacent pairs of atoms are present selected from the group consisting of O—O, O—NR b , S—NR b , O—S, O—S(O), O—S(O) 2 , and S—S.

16 . The dienophile according to claim 1 , wherein the dienophile comprises a trans-cyclooctene moiety of formula (1b):

wherein X D is as defined in claim 1 ;

wherein, in addition to the optional presence of at most two exocyclic bonds fixed in the same plane, wherein each R c is independently selected from the group consisting of H, alkyl, aryl, OR′, SR′, S(═O) 2 R′″, F, SO 3 H, PO 3 H, NO 2 , CN, CF 3 , CF 2 —R′, C(═O)R′, C(═S)R′, C(═O)NR′R″, C(═S)NR′R″, NR′C(═O)—R′″, NR′C(═S)—R′″, NR′C(═O)O—R′″, NR′C(═S)O—R′″, NR′C(═O)S—R′″, NR′C(═S)S—R′″, NR′C(═O)NR″—R″, NR′C(═S)NR″—R″, and CR′NR″, with each R′ and each R″ independently being H, aryl or alkyl and R′″ independently being aryl or alkyl;

wherein two R a,e moieties together may form a ring;

wherein optionally one of R a and R c , or the self-immolative linker L D , is bound to C B .

17 . A dienophile of any one of the following formulae:

wherein the dotted line denotes a bond to the rest of C B and wherein the wavy line indicates a bond to the rest of C A or L D -C A , wherein L D may optionally comprise C B ;

wherein the dotted line denotes a bond to the rest of C B and wherein the wavy line indicates a bond to the rest of C A or L D -C A , wherein L D may optionally comprise C B ;

wherein the dotted line denotes a bond to the rest of C B and wherein the wavy line indicates a bond to the rest of C A or L D -C A , wherein L D may optionally comprise C B ;

wherein L D is a self-immolative linker consisting of one or more self-immolative units;

wherein each self-immolative unit is selected from the group consisting of

wherein the wiggly line indicates a bond to (O—C(O)) p or O—C(S) of X D , or to a preceding self-immolative unit; wherein the asterisk indicates a bond to C A or to a further self-immolative unit;

wherein L 2 is O, S, NH, or NR with R being alkyl or aryl; wherein each L 1 is independently H or methyl;

wherein each C A and C B are individually selected from the group consisting of biomolecules, biomolecule-binding moieties, polymers, particles, gels, fluorophores, and radiolabels.

18 . The dienophile according to claim 1 , which is of any one of the following formulae

19 . The dienophile according to claim 1 , which is of any one of the following formulae

20 . The dienophile according to claim 1 wherein n=0 and wherein each instance of R a and R b is bound directly to a construct C B .

Assignments (1)
CHANGE OF ADDRESS Recorded Dec 16, 2021
From: TAGWORKS PHARMACEUTICALS B.V.
To: TAGWORKS PHARMACEUTICALS B.V.
Reel/Frame 058522/0348 →
Priority Claims (1)
EP 12193911 · Nov 22, 2012 · regional
Continuity (2)
Continuation 14646619 · Nov 22, 2013
Related Publication 20210002320A1 · Jan 7, 2021
References Cited (111)
US 4486414A · Pettit et al. · 1984 [cited by applicant]
US 4486444A · Shepard et al. · 1984 [cited by applicant]
US 4879278A · Pettit et al. · 1989 [cited by applicant]
US 4986988A · Ettit et al. · 1991 [cited by applicant]
US 5138036A · Pettit et al. · 1992 [cited by applicant]
US 5198560A · Kadow · 1993 [cited by applicant]
US 5410024A · Pettit et al. · 1995 [cited by applicant]
US 5504191A · Pettit et al. · 1996 [cited by applicant]
US 5521284A · Pettit et al. · 1996 [cited by applicant]
US 5530097A · Pettit et al. · 1996 [cited by applicant]
US 5599902A · Pettit et al. · 1997 [cited by applicant]
US 5635483A · Pettit et al. · 1997 [cited by applicant]
US 5663149A · Pettit et al. · 1997 [cited by applicant]
US 5665860A · Pettit et al. · 1997 [cited by applicant]
US 5780588A · Pettit et al. · 1998 [cited by applicant]
US 6034065A · Pettit et al. · 2000 [cited by applicant]
US 6239104B1 · Pettit et al. · 2001 [cited by applicant]
US 6323315B1 · Pettit et al. · 2001 [cited by applicant]
US 7005132B2 · Cubicciotti · 2006 [cited by applicant]
US 9421274B2 · Robillard et al. · 2016 [cited by applicant]
US 9427482B2 · Rossin et al. · 2016 [cited by applicant]
US 9463256B2 · Lub et al. · 2016 [cited by applicant]
US 9913921B2 · Robillard et al. · 2018 [cited by applicant]
US 9931408B2 · Robillard et al. · 2018 [cited by applicant]
US 10004810B2 · Robillard et al. · 2018 [cited by applicant]
US 10376594B2 · Robillard et al. · 2019 [cited by applicant]
US 10927139B2 · Robillard et al. · 2021 [cited by applicant]
US 10967069B2 · Robillard et al. · 2021 [cited by applicant]
US 20090023916A1 · Fox et al. · 2009 [cited by applicant]
US 20150297741A1 · Robillard · 2015 [cited by applicant]
WO 2010051530A2 · 2010 [cited by applicant]
WO 2010119382A1 · 2010 [cited by applicant]
WO 2010119389A2 · 2010 [cited by applicant]
WO 2012012612A2 · 2012 [cited by applicant]
WO 2012049624A1 · 2012 [cited by applicant]
WO 2012085789A1 · 2012 [cited by applicant]
WO 2012156919 · 2012 [cited by applicant]
WO 2012156918A1 · 2012 [cited by applicant]
WO 2014065860 · 2014 [cited by applicant]
WO 2014081301 · 2014 [cited by applicant]
WO 2014081303 · 2014 [cited by applicant]
WO 2016025480 · 2016 [cited by applicant]
WO 2018004338 · 2018 [cited by applicant]
Ajay et al., “Diversity-Oriented Synthesis of cis-3,4-Dihydroxylated Piperidine and Its Higher Saturated and Unsaturated Homologues from d-Ribose and Their Glycosidase-Inhibition Study”, SYNLETT, 2016, Vo. 27, No. 19, p… [cited by applicant]
Alley, S; Okeley N; Senter, PD; et al. “Antibody-drug conjugates: targeted drug delivery for cancer.” Current Opinion in Chemical Biology, (2010), 14:529-537. [cited by applicant]
Banker, G.S. et al., “B. Prodrugs”, Modern Pharmaceutics, 3ed, Marcel Dekker, New York, 1996, p. 451 and 596. [cited by applicant]
Haun, Jered B. et al , “Bioorthogonal Chemistry Amplifies Nanoparticle Binding and Enhances the Sensitivity of Cell Detection”, Nature Nanotechnology, vol. 5, Sep. 2010, pp. 660-665. [cited by applicant]
International Search Report and Written Opinion for Corresponding International Application No. PCT/NL2019/050271 (10 Pages) ( Oct. 23, 2019). [cited by applicant]
International Search Report and Written Opinion for Corresponding International Application No. PCT/NL2019/050272 (9 Pages) (Oct. 9, 2019). [cited by applicant]
International Search Report and Written Opinion for Corresponding International Application No. PCT/NL2020/050386 (17 Pages) (Nov. 5, 2020). [cited by applicant]
International Search Report and Written Opinion for Corresponding International Application No. PCT/NL2020/050387 (9 Pages) (Aug. 25, 2020). [cited by applicant]
International Search Report and Written Opinion for Corresponding International Application No. PCT/NL2020/050388 (9 Pages) (Aug. 19, 2020). [cited by applicant]
Rossin et al., “Highly Reactive trans-Cyclooctene Tags with Improved Stability for Diels-Alder Chemistry in Living Systems”, Bioconjugate Chemistry, 2013, vol. 24, No. 7, pp. 1210-1217. [cited by applicant]
Rossin et al., “Triggered Drug Release from an Antibody-Drug Conjugate Using Fast “Click-to-Release” Chemistry In Mice”, Bioconjugate Chemistry, 2016, vol. 27, No. 7, pp. 1697-1706. [cited by applicant]
Rossin, R. et al. “In vivo chemistry for pretargeted tumor imaging in live mice”. Angewandte Chemie International Edition, (2010), 49, 3375-3378. [cited by applicant]
Thalhammer, F. et al. Reaktivitat Einfacher Offenkettiger Und Cyclischer Dienophile Bei Diels-alder-reaktionen mil inversem elektronenbedarf. Tetrahedron Letters (1990), 31 (47), 6851-6854. (See English abstract.). [cited by applicant]
Van Brakel, R. et al. “A doxorubicin prodrug activated by the staudinger reaction”. Bioconjugate Chem. (2008), 19, 714-718. [cited by applicant]
White et al., “Synthesis of Polyhydroxylated Pyrrolizidine Alkaloids of the Alexine Family by Tandem Ring-Closing Metathesis-Transannular Cyclization. (+)-Australine”, Journal of Organic Chemistry, 2000, vol. 65, No. 26… [cited by applicant]
Whitham, G.H. et al. “trans-Cycloalkenes. Part I. (1 RS,2RS)-Irans-Cyclo-oct-2-en-1-ol”. Journal Chem. Society, (1971), 883-886. [cited by applicant]
Whitham, G.H. et al. “trans-Cycloalkenes. Part II. Application of the Dioxolan Olefin Synthesis to the Stereospecific Formation of trans-Cyclo-octene Derivatives. (1 SR,2RS)-Irans-Cyclo-oct-2-en-1-ol”. Journal Chem. Soc… [cited by applicant]
Whitham, G.H. et al. “trans-Cycloalkenes. Part III. Stereochemistry and mechanism of some reactions of diastereoisomeric 3-substituted trans-cyclo-octenes”. Journal Chem. Society, (1971), 891-896. [cited by applicant]
Wiessler, Manfred; et al. “Extension of the PNA world by functionalized PNA monomers eligible candidates for Inverse Diels Alder Click Chemistry”, Int. Journal of Medical Science, Jun. 27, 2010, 7(4):213-223. [cited by applicant]
Xia,Y. et al. “Shape-Controlled Synthesis of Metal Nanocrystals: Simple Chemistry Meets Complex Physics?”, Angewandte Chemie International Edition (2009), 48, 1-5. [cited by applicant]
U.S. Appl. No. 13/877,725, filed Apr. 4, 2013, U.S. Pat. No. 9,463,256, Oct. 11, 2016, Pretargeting Kit, Method and Agents Used Therein. [cited by applicant]
U.S. Appl. No. 13/994,783, filed Jun. 17, 2013, U.S. Pat. No. 9,427,482, Aug. 30, 2016, Agents for Clearing Biomolecules From Circulation. [cited by applicant]
U.S. Appl. No. 14/115,455, filed Nov. 4, 2013, U.S. Pat. No. 9,913,921, Mar. 13, 2018, Pretargeting Kit for Imaging or Therapy Comprising a Trans-Cyclooctene Dienophile and a Diene. [cited by applicant]
U.S. Appl. No. 14/117,246, filed Nov. 12, 2013, U.S. Pat. No. 9,421,274, Aug. 23, 2016, Bio-Orthogonal Drug Activation. [cited by applicant]
U.S. Appl. No. 15/233,283, filed Nov. 23, 2016, U.S. Pat. No. 10,004,810, Jun. 26, 2018, Bio-Orthogonal Drug Activation. [cited by applicant]
U.S. Appl. No. 14/117,655, filed Nov. 15, 2013, U.S. Pat. No. 9,931,408, Apr. 3, 2018, Bio-Orthogonal Drug Activation. [cited by applicant]
U.S. Appl. No. 14/983,858, filed Dec. 30, 2015, U.S. Pat. No. 10,376,594, Aug. 13, 2019, Bio-Orthogonal Drug Activation. [cited by applicant]
U.S. Appl. No. 16/512,038, filed Jul. 15, 2019, U.S. Pat. No. 10,967,069, Apr. 6, 2021, Bio-Orthogonal Drug Activation. [cited by applicant]
U.S. Appl. No. 17/169,217, filed Feb. 5, 2021, Bio-Orthogonal Drug Activation. [cited by applicant]
U.S. Appl. No. 14/646,619, filed May 21, 2015, U.S. Pat. No. 10,927,139, Feb. 23, 2021, Chemically Cleavable Group. [cited by applicant]
U.S. Appl. No. 17/052,925, filed Nov. 4, 2020, Compounds Comprising a Linker for Increasing Transcyclooctene Stability. [cited by applicant]
U.S. Appl. No. 17/052,928, filed Nov. 4, 2020, Tetraines for High Click Conjugation Yield in Vivo and High Click Release Yield. [cited by applicant]
U.S. Appl. No. 17/619,791 filed Dec. 16, 2021, Compunds for Fast and Efficient Click Release. [cited by applicant]
U.S. Appl. No. 17/619,794, filed Dec. 16, 2021, Tetrazines for High Click Release Speed and Yield. [cited by applicant]
U.S. Appl. No. 17/619,796, filed Dec. 16, 2021, Agents for Cleaving Labels from Biomolecules in Vivo. [cited by applicant]
Senter, P .D. et al. “Antibody-drug conjugates: targeted drug delivery for cancer.” Current Opinion in Chemical Biology, (2010), 14:529-537. [cited by applicant]
Klopman, G. et al. “Computer automated log P calculations based on an extended group contribution approach”. Joumal Chem. Inf. Comput. Sci. (1994), 34, 752-781. [cited by applicant]
Thakur, A. et al. “Cancer therapy with bispecific antibodies: Clinical experience”. Current Opinion in Molecular Therapeutics, (2010), 12(3), 340-349. [cited by applicant]
Thalhammer, F. et al. Reaktivitat Einfacher Offenkettiger Und Cyclischer Dienophile Bei Diels-alder-reaktionen mil inversem elektronenbedarf. Tetrahedron Letters (1990), 31 (47), 6851-6854. [cited by applicant]
Wijnen, J.W. et al. “Substitute effects on an inverse electron demand hetero diels-alder reaction in aqueous solution and organic solvents: cycloaddition of substituted styrenes to Di(2-pyridyl)-1,2,4,5-tetrazine”. Jour… [cited by applicant]
Blackman, M.L. et al. “The tetrazine ligation: fast bioconjugation based on inverse-electron-demand Diels-Alder reactivity”. Journal of American Chemical Society, (2008), 130(41), 13518-13519. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/IB2012/052446, Nov. 19, 2013, 10 Pages. [cited by applicant]
Devaraj, N.K. et al. “Fast and sensitive pretargeted labeling of cancer cells via tetrazine/trans-cyclooctene cycloaddition”. Angewandte Chemie International Edition, (2009), 48(38): 7013-1016. [cited by applicant]
Xia. et al. Angewandte Chemie International Edition (2009), 48, 1-5. [cited by applicant]
Tranoy-Opalinski, I. et al. “Design of self-Immolative linkers for tumour activated prodrug therapy”. Anti-Cancer Agents in Medicinal Chemistry, (2008), 8, 618-637. [cited by applicant]
Greenwald, R.B. et al. “Drug delivery systems employing 1,4-or 1,6-elimination: Poly(ethylene glycol) prodrugs of amine-containing compounds”. Journal Med. Chem. (1999), 42, 3657-3667. [cited by applicant]
Blencowe, C.A. et al. “Self-immolative linkers in polymeric delivery systems”. Polymer Chemistry, (2011 ), 2, 773-790. [cited by applicant]
Cere, V. et al. “Olefin Inversion. Protection of the sulfide function in the stereospecific synthesis of trans-Thiacyclooct-4-ene”. Journal of Organic Chemistry, (1980), 45, 261-264. [cited by applicant]
Prevost, M. et al. “Insertions of silylenes into vinyl epoxides: Diastereoselective synthesis of functionalized, optically active trans-Dioxasilacyclooctenes”. Journal of the American Chemical Society, (2009), 131, 1418… [cited by applicant]
Devaraj, N.K. et al. “Tetrazine-based cycloadditions: Application to Pretargeted live cell imaging”,Bioconjugate Chem., (2008), 19(12), 2297-2299. [cited by applicant]
Geldard, J.F. et al. “The organic chemistry of a new weak field tridentate chelating agent. 3,5-Di(2-pyridyl)-1,2,4-triazole”. Journal Organic Chemistry. (1965), 30, 318-319. [cited by applicant]
Grakauskas, V.A. et al. “Some 3,6-unsymmetrically disubstituted 1,2,4,5-Tetrazines”. Journal American Chemical Society, (1958), 80, 3155-3159. [cited by applicant]
Audebert, P. et al. “Synthesis of new substituted tetrazines: electrochemical and spectroscopic properties”. New Journal Chem. (2004), 28, 387-392. [cited by applicant]
Kaim, W. et al. “The new tetrafunctional (pi) acceptor ligand 3,6-Bis(2′-pyrimidyl)-1,2,4,5-tetrazine(bmtz): Diruthenium complexes of bmtz and of its 1,4-Dihydro form”. Z. Naturforsch, 50b, 123-127 (1995). [cited by applicant]
Choe, Y.H. et al. “Anticancer drug delivery systems: multi-loaded N4-acyl poly(ethylene glycol) prodrugs of ara-C. II. Efficacy in ascites and solid tumors”. Journal of Controlled Release, (2002), 79, 55-70. [cited by applicant]
Haba, K. et al. “Single-triggered trimeric prodrugs”. Angewandte Chemie International Edition. (2005), 44, 726-730. [cited by applicant]
Ingold, C.K. et al. “The Nature of the Alternating effect in carbon chains. Part XXII. An attempt further to define the probable mechanism of orientation in aromatic substitution”. Journal Chem. Society. (1927), 2918-29… [cited by applicant]
Mohsin, H. et al. “Radiolanthanide-labeled monoclonal antibody CC49 for radioimmunotherapy of cancer: biological comparison of DOTA conjugates and 149Pm, 166Ho, and 177Lu”. Bloconjugate Chem. (2006), 17, 485-492. [cited by applicant]
Thompson, S. et al. “The construction and in vitro testing of photo-activalable cancer targeting folaled anti-CD3 conjugates”. Biochemical and Biophysical Research Communications, (2008), 366, 526-531. [cited by applicant]
Brakel, van, R. et al. “A doxorubicin prodrug activated by the staudinger reaction”. Bioconujugate Chem. (2008), 19, 714-718. [cited by applicant]
Viswanadhan, V.N. et al. “Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions an… [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2012/052446, Oct. 23, 2012, 14 Pages. [cited by applicant]
Wolff, Manfred E. “Burgers Medicinal Chemistry”, 5ed, Part 1 John Wiley & Sons, 1995, pp. 975-977. [cited by applicant]
Banker, G.S. et al., Modem Pharmaceutices, 3ed Marcel Dekker, New York, 1996, p. 451 and 596. [cited by applicant]
Atfah, M., “Diels-Alder Reactions of 3,6-Diphenyl-1,2,3,4,5-Tetrazinenad 3,6-Di(2-Pyridyl)-1,2,4,5,-tetrazine with some 1-Morpholinocycloalkenes,” J. Heterocyclic Chem, 26, 717 (1989). [cited by applicant]
Rossin, R. et al., “In Vivo Chemistry for Pretargeted Tumor Imaging in Live Mice,” Angew Chem In led 2010, 49.375-3378. [cited by applicant]
Thomas, J., et al., “Proligands with protease-regulated binding activity identified from cell-displayed prodomain libraries,” Protein Science 2009, vol. 18:2053-2059. [cited by applicant]
International Search Report and Written Opinion for Corresponding International Application No. PCT/NL2013/050850 (9 Pages) (Feb. 11, 2014). [cited by applicant]